FMQ Stock Chart & Stats
CHF8.81
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF8.13 - CHF8.93
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
CHF1.11B
Enterprise ValueCHF5.39K
Total Cash (Recent Filing)CHF476.60M
Total Debt (Recent Filing)CHF4.28B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 03, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.02
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.84
Price to Sales (P/S)0.50
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF11.46Price Target Upside― Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)1.09
Revenue Forecast (FY)CHF2.93B
Bulls Say, Bears Say
Bulls Say
Pipeline And New Actives MomentumA growing pipeline of new actives that doubled YoY signals structural revenue diversification beyond legacy products. New launches typically carry higher margin potential, extend patent-protected windows, and improve pricing and mix over multiple seasons, supporting medium-term revenue and margin recovery if registrations proceed.
Isoflex EU Regulatory ApprovalEU approval for Isoflex is a durable strategic win that opens a large, high-regulatory-barrier market starting in 2027. Regulatory exclusivity and scale across >55M hectares can create a multi-year revenue stream, support premium positioning in Europe, and help offset competitive pressures elsewhere.
Active Deleveraging And Liquidity ActionsManagement is executing a credible deleveraging plan combining strategic equity, asset sales, licensing revenue and secured refinancing. These actions materially increase near-term liquidity and lengthen maturities, reducing immediate refinancing risk and providing runway for R&D and commercialization execution.
Bears Say
Elevated Leverage And Impaired EquitySubstantially higher leverage and effectively zero equity materially constrain financial flexibility. High debt loads increase interest costs and covenant risk, limit discretionary R&D and capital spending, and make the company highly dependent on successful asset sales and execution to avoid liquidity stress over the medium term.
Sharp Profitability DeteriorationA swing to deep net losses and negative operating income undermines retained earnings and the firm’s ability to self-fund growth. Persistent profit compression reduces reinvestment capacity, pressures stakeholder confidence, and heightens reliance on non‑operating proceeds and restructuring to restore normalized margins.
Inconsistent Cash Generation And Tight FCF OutlookVolatile cash flow and a breakeven FCF outlook that depends on restructuring spend and asset-sale proceeds raise execution risk. Inconsistent cash conversion limits the company’s ability to pay down debt, invest in commercialization of new actives, and absorb downside shocks without further financing or dilution.
FMC News
FMQ FAQ
What was Fmc Corp.’s price range in the past 12 months?
Fmc Corp. lowest stock price was CHF8.13 and its highest was CHF8.93 in the past 12 months.
What is Fmc Corp.’s market cap?
Fmc Corp.’s market cap is CHF1.11B.
When is Fmc Corp.’s upcoming earnings report date?
Fmc Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 71 days.
How were Fmc Corp.’s earnings last quarter?
Fmc Corp. released its earnings results on Jul 29, 2026. The company reported CHF0.21 earnings per share for the quarter, beating the consensus estimate of CHF0.177 by CHF0.032.
Is Fmc Corp. overvalued?
According to Wall Street analysts Fmc Corp.’s price is currently Undervalued.
Does Fmc Corp. pay dividends?
Fmc Corp. does not currently pay dividends.
What is Fmc Corp.’s EPS estimate?
Fmc Corp.’s EPS estimate is 0.09.
How many shares outstanding does Fmc Corp. have?
Currently, no data Available
What happened to Fmc Corp.’s price movement after its last earnings report?
Fmc Corp. reported an EPS of CHF0.21 in its last earnings report, beating expectations of CHF0.177. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Fmc Corp.?
Currently, no hedge funds are holding shares in CH:FMQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
FMC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF11.46 (― Upside)
CHF11.46 (― Upside)
Blogger Sentiment
Neutral
CH:FMQ Sentiment 56%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.63%
Trailing 12-Months
Company Description
Fmc Corp.
FMC Corporation functions as an agricultural science enterprise, delivering products for crop safeguarding, plant wellness, and professional pest and turf management. The company is responsible for creating, commercializing, and selling various crop protection chemicals, including insecticides, herbicides, and fungicides, alongside biologicals, crop nutrition supplements, and seed treatment solutions. These innovations are employed in farming to boost harvest quantity and quality by mitigating diverse insect infestations, weed growth, and plant ailments. Furthermore, its solutions cater to non-agricultural sectors for general pest control. FMC distributes its comprehensive product range through its proprietary sales teams, in collaboration with alliance partners, and via independent distributors and sales representatives. Established in 1883, FMC Corporation is based in Philadelphia, Pennsylvania, and conducts operations across North America, Latin America, Europe, the Middle East, Africa, and Asia.
FMQ Company Deck
FMQ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced operational and strategic positives — Q1 results beat guidance, new active ingredients are gaining momentum, Isoflex EU approval and debt-reduction actions are meaningful achievements — against material near-term financial headwinds including price declines, significant Q2 and full-year profit erosion, weak Q1 free cash flow and elevated leverage. Management expects H1 to be an earnings trough with recovery in H2 and into 2027, but execution on asset sales, registrations and cost actions will be critical.View all CH:FMQ earnings summariesFMQ Revenue Breakdown
45.36% Insecticides
35.96% Herbicides
10.46% Fungicides
5.51% Plant Health
2.71% Other
